Precision medicine (PM) is fundamentally transforming the healthcare and life sciences (HCLS) industry. Often viewed as the future of medicine, PM is becoming increasingly important to stakeholders across the entire HCLS ecosystem, including academic medical centers, diagnostics and biopharma companies, laboratories, healthcare providers, payers and data providers. Theses stakeholders recognize that medicine is moving from a "one-size-fits-all" mentality to an approach that diagnoses and treats disease tailored to an individual's genes, environment, and lifestyle.
In this article, we focus on chimeric antigen receptor T-cell (CAR T) therapy, a type of cell and gene therapy (C>) that represents one of the most exciting and high-profile areas of precision medicine. The authors discuss the disruption caused by CAR T to standard business models in the life sciences industry and its implications for transfer pricing.
